Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

214
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
214
Cancer Survival Analysis01:21

Cancer Survival Analysis

319
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
319
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

540
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
540
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

54
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
54
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

23
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
23
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

117
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
117

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Community pharmacists are not yet ready to manage oral anti-cancer agents: beyond safe dispensing and basic education.

The International journal of pharmacy practice·2026
Same author

Identification of health indicators for a health equity scorecard in ambulatory care pharmacy practice.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Content validation of a pre-treatment oral oncolytic non-adherence estimator (ORACLE).

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

Quantitative Lesion-Level Modeling Reveals Organ-Dependent Therapeutic Response.

Clinical pharmacology and therapeutics·2026
Same author

Characterizing pharmacist impact in maintenance therapy for adolescent and young adults with acute lymphoblastic leukemia treated with CALGB 10403 protocol.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

Integrating Patient Engagement into Clinical Pharmacology and Pharmacometrics: Bringing the Patient Voice into Data-Driven Science.

Clinical pharmacology and therapeutics·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Camrelizumab, a patinib and radiotherapy in locally advanced, unresectable hepatocellular carcinoma: a phase 2 study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Updated: May 25, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Revolutionizing Patient-Reported Outcomes Analysis for Oncology Drug Development Using Population Models.

Jiawei Zhou1,2, Benyam Muluneh1,2, Quefeng Li3

  • 1Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 27, 2025
PubMed
Summary
This summary is machine-generated.

Population modeling offers a powerful solution for analyzing patient-reported outcomes (PRO) in oncology trials. This approach effectively handles data variability and missing values, improving treatment efficacy analysis.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

1.4K

Related Experiment Videos

Last Updated: May 25, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

1.4K

Area of Science:

  • Clinical Trials
  • Statistical Modeling
  • Oncology

Background:

  • Patient-reported outcomes (PRO) are critical clinical endpoints in oncology trials.
  • Traditional statistical methods struggle with PRO data's variability and missingness.
  • Inappropriate PRO analysis can lead to inaccurate treatment efficacy conclusions.

Purpose of the Study:

  • To highlight the value of population modeling for PRO data analysis in oncology.
  • To demonstrate how population models can overcome challenges in PRO data analysis.
  • To encourage the adoption of population modeling in oncology drug development.

Main Methods:

  • Application of individual participant data and population models.
  • Incorporation of covariates, between-subject variability, and measurement noise.
  • Leveraging population information for accurate estimations with missing or sparse data.

Main Results:

  • Population models effectively handle high variability in PRO measurements.
  • Accurate estimations are provided for participants with missing data.
  • Potential for predicting long-term PRO dynamics exists.

Conclusions:

  • Population modeling can revolutionize PRO data analysis in oncology.
  • This approach enhances understanding of treatment impact on patients.
  • Adoption of population modeling can improve decision-making and patient care.